Operative Management of Colorectal Liver Metastases

Gilles Mentha; Sylvain Terraz; Axel Andres; Christian Toso; Laura Rubbia-Brandt; Pietro Majno

doi:10.1055/s-0033-1351785

Seminars in Liver Disease, Inhaltsverzeichnis

Semin Liver Dis 2013; 33(03): 262-272
DOI: 10.1055/s-0033-1351785

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Operative Management of Colorectal Liver Metastases

Autoren

Gilles Mentha

¹Divisions of Transplantation and Visceral Surgery, Department of Surgery, University Hospitals of Geneva, Geneva, Switzerland

⁴Hepato-Pancreato-Biliary Center, University Hospitals of Geneva, Geneva, Switzerland
Sylvain Terraz

²Division of Radiology, Department of Medical Imaging and Information Sciences University Hospitals of Geneva, Geneva, Switzerland

⁴Hepato-Pancreato-Biliary Center, University Hospitals of Geneva, Geneva, Switzerland
Axel Andres

¹Divisions of Transplantation and Visceral Surgery, Department of Surgery, University Hospitals of Geneva, Geneva, Switzerland
Christian Toso

¹Divisions of Transplantation and Visceral Surgery, Department of Surgery, University Hospitals of Geneva, Geneva, Switzerland

⁴Hepato-Pancreato-Biliary Center, University Hospitals of Geneva, Geneva, Switzerland
Laura Rubbia-Brandt

³Division of Clinical Pathology, Department of Pathology, University Hospitals of Geneva, Geneva, Switzerland

⁴Hepato-Pancreato-Biliary Center, University Hospitals of Geneva, Geneva, Switzerland
Pietro Majno

¹Divisions of Transplantation and Visceral Surgery, Department of Surgery, University Hospitals of Geneva, Geneva, Switzerland

⁴Hepato-Pancreato-Biliary Center, University Hospitals of Geneva, Geneva, Switzerland

Abstract

In this review, the authors describe the management of patients with colorectal liver metastases in the era of effective chemotherapies and advanced interventional radiology. They give special attention to the surgical procedures that decrease the operative mortality and morbidity and produce clear margins. They discuss the best timing for chemotherapy, resection of the primary tumor, and resection of the liver metastases in an effort to improve long-term survival. The use of preoperative portal vein embolization, two-stage hepatectomy for bilobar synchronous liver metastases, and the liver-first strategy have allowed for treatment of patients with advanced disease with a curative intent, and to obtain 5-year overall survival of 30 to 60% despite poor prognostic factors and a cure (no recurrence at 10 years) in more than 20% of patients. These rates would have been unimaginable only two decades ago.

Keywords

colorectal liver metastases - operative management - margin - reversed approach - long-term survival

Volltext

Referenzen

References
1 Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?. J Clin Oncol 2005; 23 (33) 8490-8499
2 Mentha G, Majno P, Terraz S , et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol 2007; 33 (Suppl. 02) S76-S83
3 Folprecht G, Gruenberger T, Bechstein WO , et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11 (1) 38-47
4 Nordlinger B, Sorbye H, Glimelius B , et al; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371 (9617) 1007-1016
5 Stremitzer S, Stift J, Gruenberger B , et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99 (11) 1575-1582
6 Belghiti J, Hiramatsu K, Benoist S, Massault PF, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191 (1) 38-46
7 Strong RW, Lynch SV, Wall DR, Ong TH. The safety of elective liver resection in a special unit. Aust N Z J Surg 1994; 64 (8) 530-534
8 Sharma A, Deeb AP, Iannuzzi JC, Rickles AS, Monson JR, Fleming FJ. Tobacco smoking and postoperative outcomes after colorectal surgery. Ann Surg 2012; . epub ahead of print
9 Andres A, Toso C, Moldovan B , et al. Complications of elective liver resections in a center with low mortality: a simple score to predict morbidity. Arch Surg 2011; 146 (11) 1246-1252
10 Choti MA, Bowman HM, Pitt HA , et al. Should hepatic resections be performed at high-volume referral centers?. J Gastrointest Surg 1998; 2 (1) 11-20
11 Fong Y, Gonen M, Rubin D, Radzyner M, Brennan MF. Long-term survival is superior after resection for cancer in high-volume centers. Ann Surg 2005; 242 (4) 540-544 , discussion 544–547
12 Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of volume of surgery and specialization on patient outcome. Br J Surg 2007; 94 (2) 145-161
13 Csikesz NG, Simons JP, Tseng JF, Shah SA. Surgical specialization and operative mortality in hepato-pancreatico-biliary (HPB) surgery. J Gastrointest Surg 2008; 12 (9) 1534-1539
14 Berney T, Mentha G, Morel P. Total vascular exclusion of the liver for the resection of lesions in contact with the vena cava or the hepatic veins. Br J Surg 1998; 85 (4) 485-488
15 Kooby DA, Stockman J, Ben-Porat L , et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003; 237 (6) 860-869 , discussion 869–870
16 de Jong MC, Mayo SC, Pulitano C , et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg 2009; 13 (12) 2141-2151
17 Zorzi D, Mullen JT, Abdalla EK , et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006; 10 (1) 86-94
18 Dhir M, Lyden ER, Wang A, Smith LM, Ullrich F, Are C. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg 2011; 254 (2) 234-242
19 Pawlik TM, Scoggins CR, Zorzi D , et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241 (5) 715-722 , discussion 722–724
20 Holdhoff M, Schmidt K, Diehl F , et al. Detection of tumor DNA at the margins of colorectal cancer liver metastasis. Clin Cancer Res 2011; 17 (11) 3551-3557
21 Mentha G, Terraz S, Morel P , et al. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases. Br J Surg 2009; 96 (1) 95-103
22 Maru DM, Kopetz S, Boonsirikamchai P , et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010; 34 (9) 1287-1294
23 Falcone A, Ricci S, Brunetti I , et al; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25 (13) 1670-1676
24 Seium Y, Stupp R, Ruhstaller T , et al. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005; 16 (5) 762-766
25 Saltz LB, Clarke S, Díaz-Rubio E , et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26 (12) 2013-2019
26 Hurwitz H, Fehrenbacher L, Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23) 2335-2342
27 Vauthey JN, Pawlik TM, Ribero D , et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24 (13) 2065-2072
28 Rubbia-Brandt L, Audard V, Sartoretti P , et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15 (3) 460-466
29 Wicherts DA, de Haas RJ, Andreani P , et al. Impact of portal vein embolization on long-term survival of patients with primarily unresectable colorectal liver metastases. Br J Surg 2010; 97 (2) 240-250
30 Adam R, De Gramont A, Figueras J , et al; Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012; 17 (10) 1225-1239
31 Kishi Y, Madoff DC, Abdalla EK , et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified?. Surgery 2008; 144 (5) 744-751
32 Goéré D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg 2006; 10 (3) 365-370
33 Elias D, De Baere T, Roche A, , Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg 1999; 86 (6) 784-788
34 Hoekstra LT, van Lienden KP, Doets A, Busch ORC, Gouma DJ, van Gulik TM. Tumor progression after preoperative portal vein embolization. Ann Surg 2012; 256 (5) 812-817 , discussion 817–818
35 Weng M, Zhang Y, Zhou D , et al. Radiofrequency ablation versus resection for colorectal cancer liver metastases: a meta-analysis. PLoS ONE 2012; 7 (9) e45493
36 Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232 (6) 777-785
37 Narita M, Oussoultzoglou E, Jaeck D , et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 2011; 98 (10) 1463-1475
38 Tanaka K, Hiroshima Y, Nakagawa K , et al. Two-stage hepatectomy with effective perioperative chemotherapy does not induce tumor growth or growth factor expression in liver metastases from colorectal cancer. Surgery 2013; 153 (2) 179-188
39 Brouquet A, Abdalla EK, Kopetz S , et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 2011; 29 (8) 1083-1090
40 Muratore A, Zimmitti G, Ribero D, Mellano A, Viganò L, Capussotti L. Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?. Ann Surg Oncol 2012; 19 (4) 1310-1315
41 Turrini O, Ewald J, Viret F, Sarran A, Goncalves A, Delpero JR. Two-stage hepatectomy: who will not jump over the second hurdle?. Eur J Surg Oncol 2012; 38 (3) 266-273
42 Stella M, Dupre A, Chabaud S , et al. A comparative study of patients with and without associated digestive surgery in a two-stage hepatectomy setting. Langenbecks Arch Surg 2012; 397 (8) 1289-1296
43 Karoui M, Vigano L, Goyer P , et al. Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. Br J Surg 2010; 97 (9) 1354-1362
44 Schnitzbauer AA, Lang SA, Goessmann H , et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255 (3) 405-414
45 Alvarez FA, Ardiles V, Sanchez Claria R, Pekolj J, de Santibañes E. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks. J Gastrointest Surg 2013; 17 (4) 814-821
46 Aloia TA, Vauthey JN. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): what is gained and what is lost?. Ann Surg 2012; 256 (3) e9 , author reply e16–e19
47 Dokmak S, Belghiti J. Which limits to the “ALPPS” approach?. Ann Surg 2012; 256 (3) e6 , author reply e16–e17
48 Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe?. Ann Surg 2012; 255 (2) 237-247
49 Adam R, Bhangui P, Poston G , et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?. Ann Surg 2010; 252 (5) 774-787
50 Benoist S, Pautrat K, Mitry E, Rougier P, Penna C, Nordlinger B. Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. Br J Surg 2005; 92 (9) 1155-1160
51 Muratore A, Zorzi D, Bouzari H , et al. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?. Ann Surg Oncol 2007; 14 (2) 766-770
52 Thelen A, Jonas S, Benckert C , et al. Simultaneous versus staged liver resection of synchronous liver metastases from colorectal cancer. Int J Colorectal Dis 2007; 22 (10) 1269-1276
53 Reddy SK, Pawlik TM, Zorzi D , et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol 2007; 14 (12) 3481-3491
54 Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg 2003; 90 (8) 956-962
55 Chua HK, Sondenaa K, Tsiotos GG, Larson DR, Wolff BG, Nagorney DM. Concurrent vs. staged colectomy and hepatectomy for primary colorectal cancer with synchronous hepatic metastases. Dis Colon Rectum 2004; 47 (8) 1310-1316
56 Martin II RCG, Augenstein V, Reuter NP, Scoggins CR, McMasters KM. Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 2009; 208 (5) 842-850 , discussion 850–852
57 Kaibori M, Iwamoto S, Ishizaki M , et al. Timing of resection for synchronous liver metastases from colorectal cancer. Dig Dis Sci 2010; 55 (11) 3262-3270
58 Capussotti L, Vigano' L, Ferrero A, Lo Tesoriere R, Ribero D, Polastri R. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 2007; 14 (3) 1143-1150
59 de Haas RJ, Adam R, Wicherts DA , et al. Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. Br J Surg 2010; 97 (8) 1279-1289
60 Slesser AAP, Simillis C, Goldin R, Brown G, Mudan S, Tekkis PP. A meta-analysis comparing simultaneous versus delayed resections in patients with synchronous colorectal liver metastases. Surg Oncol 2013; 22 (1) 36-47
61 Chiappa A, Biffi R, Bertani E , et al. Surgical outcomes after total mesorectal excision for rectal cancer. J Surg Oncol 2006; 94 (3) 182-193 , discussion 181
62 Tran CL, Udani S, Holt A, Arnell T, Kumar R, Stamos MJ. Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. Am J Surg 2006; 192 (6) 873-877
63 Matthiessen P, Hallböök O, Rutegård J, Simert G, Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 2007; 246 (2) 207-214
64 Salmenkylä S, Kouri M, Osterlund P , et al. Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial. Scand J Surg 2012; 101 (4) 275-282
65 Mantion G, Panis Y. Mortalité et morbidité en chirurgie colorectale. Rapport de l'Association de Chirurgie 2003. Paris, France: l'Association de Chirurgie; 2003. . Monographie, Arnette Edition. September 2003
66 O'Reilly MS, Holmgren L, Shing Y , et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79 (2) 315-328
67 O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2 (6) 689-692
68 Peeters CF, de Waal RM, Wobbes T, Westphal JR, Ruers TJ. Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. Int J Cancer 2006; 119 (6) 1249-1253
69 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230 (3) 309-318 , discussion 318–321
70 Mala T, Bøhler G, Mathisen O, Bergan A, Søreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome?. World J Surg 2002; 26 (11) 1348-1353
71 Andres A, Majno PE, Morel P , et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol 2008; 15 (1) 134-143
72 Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Arch Surg 2004; 139 (11) 1168-1172
73 Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93 (7) 872-878
74 Gervaz P, Rubbia-Brandt L, Andres A , et al. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. Ann Surg Oncol 2010; 17 (10) 2714-2719
75 O'Rourke TR, Welsh FK, Rees M. Comment on: Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006; 93: 872-878
76 Verhoef C, van der Pool AEM, Nuyttens JJ, Planting AST, Eggermont AMM, de Wilt JHW. The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum 2009; 52 (1) 23-30
77 de Jong MC, van Dam RM, Maas M , et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford) 2011; 13 (10) 745-752
78 Brouquet A, Mortenson MM, Vauthey JN , et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?. J Am Coll Surg 2010; 210 (6) 934-941
79 Mentha G, Roth AD, Terraz S , et al. 'Liver first' approach in the treatment of colorectal cancer with synchronous liver metastases. Dig Surg 2008; 25 (6) 430-435
80 Andres A, Toso C, Adam R , et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg 2012; 256 (5) 772-778 , discussion 778–779
81 Adam R, Wicherts DA, de Haas RJ , et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality?. J Clin Oncol 2008; 26 (10) 1635-1641
82 Blazer III DG, Kishi Y, Maru DM , et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26 (33) 5344-5351
83 Elias D, Youssef O, Sideris L , et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004; 86 (1) 4-9
84 Benoist S, Brouquet A, Penna C , et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006; 24 (24) 3939-3945
85 van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012; 19 (9) 2805-2813
86 Gaujoux S, Goéré D, Dumont F , et al. Complete radiological response of colorectal liver metastases after chemotherapy: what can we expect?. Dig Surg 2011; 28 (2) 114-120
87 Rubbia-Brandt L, Giostra E, Brezault C , et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18 (2) 299-304